Amylin-induced in Vivo Insulin Resistance in Conscious Rats: the Liver is More Sensitive to Amylin Than Peripheral Tissues

Overview

Journal Diabetologia

Specialty Endocrinology

Date 1991 Apr 1

PMID 2065857

Citations 16

Authors

S J Koopmans

A D van Mansfeld

H S Jansz

H M Krans

J K Radder

M Frolich

S F de Boer

D K Kreutter

G C ANDREWS

J A Maassen

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Amylin is a polypeptide of 37 amino acids, predominantly synthesized in pancreatic Beta cells. The peptide was suggested to be dysregulated in Type 2 (non-insulin-dependent) diabetes mellitus and it antagonized certain actions of insulin in vitro in rat muscle. This led to speculation that amylin is involved in the pathogenesis of Type 2 diabetes. We have examined the in vivo effects of rat amylin, amidated at the carboxy-terminus, on insulin-mediated carbohydrate metabolism in conscious rats, using the hyperinsulinaemic (+/- 1 nmol/l) euglycaemic (6 mmol/l) clamp technique combined with [3-3H]-glucose infusion. Basal plasma amylin levels were less than or equal to 75 pmol/l. Applied amylin levels of 220 +/- 75 pmol/l (infusion rate of 12.5 pmol/min) antagonized only the insulin action on liver, resulting in a 100% increase of hepatic glucose output. Amylin levels of 4750 +/- 750 pmol/l (infusion rate of 125 pmol/min) induced a 250% increase of insulin-inhibited hepatic glucose output and, in addition, a 30% decrease of insulin-stimulated peripheral glucose up-take. Amylin did not affect: 1) the metabolic clearance rate of insulin, 2) the levels of plasma glucagon, epinephrine, norepinephrine, and corticosterone, 3) in vitro insulin binding and insulin-stimulated receptor autophosphorylation. This suggests that amylin antagonizes insulin action via binding to a yet unknown receptor.

In Conclusion: amylin causes in vivo insulin resistance and the liver seems the predominant organ regulated by this hormone. The in vivo effects of amylin mimic the pathophysiological abnormalities of insulin action in Type 2 diabetes.

Citing Articles

Amylin receptor activation in the ventral tegmental area reduces motivated ingestive behavior.

Mietlicki-Baase E, McGrath L, Koch-Laskowski K, Krawczyk J, Reiner D, Pham T Neuropharmacology. 2017; 123:67-79.

PMID: 28552704 PMC: 5532732. DOI: 10.1016/j.neuropharm.2017.05.024.

Effect of hepatic glucose production on acute insulin resistance induced by lipid-infusion in awake rats.

Li L, Yang G World J Gastroenterol. 2004; 10(21):3208-11.

PMID: 15457577 PMC: 4611275. DOI: 10.3748/wjg.v10.i21.3208.

Dissociated secretion of islet amyloid polypeptide and insulin in serum-free culture media conditioned by human pancreatic adenocarcinoma cell lines.

Wang F, Larsson J, Abdiu A, Gasslander T, Westermark P, Adrian T Int J Pancreatol. 1997; 21(2):157-64.

PMID: 9209957 DOI: 10.1007/BF02822387.

Amylin, amyloid and age-related disease.

Cooper G, Tse C Drugs Aging. 1996; 9(3):202-12.

PMID: 8877314 DOI: 10.2165/00002512-199609030-00006.

Plasma amylin and insulin concentrations in normoglycemic and hyperglycemic cats.

Lutz T, Rand J Can Vet J. 1996; 37(1):27-34.

PMID: 8746416 PMC: 1576598.

References

Sowa R, Sanke T, Hirayama J, Tabata H, Furuta H, Nishimura S . Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogs. Diabetologia. 1990; 33(2):118-20. DOI: 10.1007/BF00401051. View

van der Gugten J, Slangen J . Release of endogenous catecholamines from rat hypothalamus in vivo related to feeding and other behaviors. Pharmacol Biochem Behav. 1977; 7(3):211-9. DOI: 10.1016/0091-3057(77)90136-8. View

Bergman R, Finegood D, Ader M . Assessment of insulin sensitivity in vivo. Endocr Rev. 1985; 6(1):45-86. DOI: 10.1210/edrv-6-1-45. View

Koopmans S, Sips H, Bosman J, Radder J, Krans H . Antilipolytic action of insulin in adipocytes from starved and diabetic rats during adenosine-controlled incubations. Endocrinology. 1989; 125(6):3044-50. DOI: 10.1210/endo-125-6-3044. View

ROBERTS A, Leighton B, Todd J, Cockburn D, Schofield P, Sutton R . Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus. Proc Natl Acad Sci U S A. 1989; 86(24):9662-6. PMC: 298561. DOI: 10.1073/pnas.86.24.9662. View

Klinkhamer M, Groen N, van der Zon G, Lindhout D, Sandkuyl L, Krans H . A leucine-to-proline mutation in the insulin receptor in a family with insulin resistance. EMBO J. 1989; 8(9):2503-7. PMC: 401243. DOI: 10.1002/j.1460-2075.1989.tb08387.x. View

Bretherton-Watt D, Gilbey S, Ghatei M, Beacham J, Bloom S . Failure to establish islet amyloid polypeptide (amylin) as a circulating beta cell inhibiting hormone in man. Diabetologia. 1990; 33(2):115-7. DOI: 10.1007/BF00401050. View

Cooper G, Willis A, Clark A, Turner R, Sim R, Reid K . Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A. 1987; 84(23):8628-32. PMC: 299599. DOI: 10.1073/pnas.84.23.8628. View

Doberne L, Greenfield M, Schulz B, Reaven G . Enhanced glucose utilization during prolonged glucose clamp studies. Diabetes. 1981; 30(10):829-35. DOI: 10.2337/diab.30.10.829. View

10.

Butler P, Chou J, Carter W, Wang Y, Bu B, Chang D . Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes. 1990; 39(6):752-6. DOI: 10.2337/diab.39.6.752. View

11.

James D, Burleigh K, Storlien L, Bennett S, Kraegen E . Heterogeneity of insulin action in muscle: influence of blood flow. Am J Physiol. 1986; 251(4 Pt 1):E422-30. DOI: 10.1152/ajpendo.1986.251.4.E422. View

12.

Westermark P, Wernstedt C, Wilander E, Sletten K . A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun. 1986; 140(3):827-31. DOI: 10.1016/0006-291x(86)90708-4. View

13.

Molina J, Cooper G, Leighton B, Olefsky J . Induction of insulin resistance in vivo by amylin and calcitonin gene-related peptide. Diabetes. 1990; 39(2):260-5. DOI: 10.2337/diab.39.2.260. View

14.

Young D, Deems R, Deacon R, McIntosh R, Foley J . Effects of amylin on glucose metabolism and glycogenolysis in vivo and in vitro. Am J Physiol. 1990; 259(3 Pt 1):E457-61. DOI: 10.1152/ajpendo.1990.259.3.E457. View

15.

Ogawa A, Harris V, McCorkle S, Unger R, Luskey K . Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. J Clin Invest. 1990; 85(3):973-6. PMC: 296519. DOI: 10.1172/JCI114528. View

16.

Fehmann H, Weber V, Goke R, Goke B, Arnold R . Cosecretion of amylin and insulin from isolated rat pancreas. FEBS Lett. 1990; 262(2):279-81. DOI: 10.1016/0014-5793(90)80210-a. View

17.

Kahn S, DAlessio D, Schwartz M, Fujimoto W, ENSINCK J, Taborsky Jr G . Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes. 1990; 39(5):634-8. DOI: 10.2337/diab.39.5.634. View

18.

Smith D, Rossetti L, Ferrannini E, Johnson C, Cobelli C, Toffolo G . In vivo glucose metabolism in the awake rat: tracer and insulin clamp studies. Metabolism. 1987; 36(12):1167-74. DOI: 10.1016/0026-0495(87)90244-7. View

19.

Murphy B . Some studies of the protein-binding of steroids and their application to the routine micro and ultramicro measurement of various steroids in body fluids by competitive protein-binding radioassay. J Clin Endocrinol Metab. 1967; 27(7):973-90. DOI: 10.1210/jcem-27-7-973. View

20.

Leighton B, Cooper G . Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature. 1988; 335(6191):632-5. DOI: 10.1038/335632a0. View